Before a gene therapy can leave manufacturing and reach a patient, it must pass a test that asks whether the product can produce the biological effect it was designed to deliver. That test is the gene therapy potency assay, and it can decide whether a batch is released, a trial proceeds, or an approval review stalls.
You can measure how much vector is present, how clean the material is, and whether the product matches its identity profile. None of that answers the hardest question: does it work in a way that reflects its intended biology? This article explains why potency testing sits at the center of Chemistry, Manufacturing, and Control (CMC) strategy, why it is difficult for gene therapies, and how you can build a defensible plan before it becomes the bottleneck.
What Is A Potency Assay—And Why Is It Different From Any Other Test?
A potency assay measures the specific ability of a product to produce a given biological effect. For gene therapy, that means the test must connect the manufactured product to its intended mechanism of action (MOA), not just confirm that a vector, transgene, or protein signal is present.
This is where potency separates itself from routine release testing. Identity testing asks whether the product is what you say it is. Purity testing asks whether unwanted materials are controlled. Titer testing measures quantity, often the amount of vector genome or infectious units. Potency asks whether the product has functional biological activity that supports the therapy’s intended effect.
That distinction matters because a gene therapy can look acceptable on several analytical tests and still fail to demonstrate suitable activity. A vial may contain the expected vector genome titer, match its identity profile, and pass purity limits, yet still have weak transduction, poor expression, impaired protein function, or loss of activity after storage. Regulators focus on potency because patients do not receive an analytical certificate; they receive a biological product that must perform.
The Regulatory Reality: Why FDA Won’t Approve A Gene Therapy Without One
The Food and Drug Administration (FDA) defines potency as the specific ability or capacity of a product, shown by suitable laboratory tests or controlled clinical data, to effect a given result. For a licensed gene therapy, that definition becomes a manufacturing requirement, not a nice-to-have scientific exercise.
FDA guidance for cellular and gene therapy products makes potency testing part of lot release, stability testing, and comparability. If one test cannot capture the product’s relevant biological activity, the agency expects a matrix of assays that together support the potency claim. A gene therapy product cannot rely on clinical promise alone if the manufacturing control system cannot demonstrate that each released lot has suitable activity.
This is why potency often becomes the manufacturing test that can make or break a gene therapy. The clinical team may see encouraging patient data, the process team may have a scalable manufacturing run, and the analytical team may have strong identity and purity methods. The program can still face serious delay if the potency assay is not suitable, not validated at the right stage, or not tied closely enough to the product’s MOA.
Why Potency Is Harder For Gene Therapy Than For Traditional Biologics
Gene therapy products often act through several biological steps. A vector may need to enter the right cell type, deliver genetic material, enable expression, produce a functional molecule, and create a measurable downstream effect. A single simple test may miss a weak link in that chain.
Adeno-associated virus (AAV) vector potency can be difficult because vector genome titer does not prove functional delivery. A lentivirus transduction assay may measure cellular entry and integration-related activity, yet still need additional readouts if the therapeutic effect depends on a specific protein function or cellular response. A reporter gene assay may give clean, quantitative results, but it may not fully represent the clinical product’s biology if the reporter system is too artificial.
The materials used in potency testing create another layer of difficulty. You may need qualified cell banks, stable reference standards, controlled reagents, and a method that works across manufacturing lots. If the target disease is rare, the relevant cell type may be hard to source or maintain. If the assay takes many days, lot release timelines become harder to manage, especially when product shelf life is short.
The Common Mistake: Confusing Quantity, Identity, Or Expression With True Potency
The most common mistake is treating vector genome titer as if it proves potency. Quantitative polymerase chain reaction (qPCR) can measure vector genomes, but quantity alone does not prove that the product can create the intended biological effect.
Expression is closer to biological function, but it still may not be enough. A test that measures messenger ribonucleic acid, transgene expression, or protein amount may show that the vector delivered genetic material and triggered production of a target molecule. If the therapeutic effect depends on protein activity, enzyme function, cell correction, or a downstream pathway, expression may be only one part of the potency story.
Identity and purity also serve different roles. Identity confirms the product’s distinguishing features. Purity evaluates unwanted process-related or product-related impurities. Potency evaluates activity. Your CMC regulatory strategy gets stronger when these assays support each other without pretending that one can replace the others.
How A Potency Assay Matrix Works: Measuring What Actually Matters
An assay matrix uses more than one test to support the potency claim. This works well when no single method can represent the full biological activity of a gene therapy product.
A matrix may combine a cell-based bioassay, a transduction assay, a protein expression assay, and a downstream functional readout. Flow cytometry may measure marker expression or corrected cell populations. Enzyme-linked immunosorbent assay (ELISA) may quantify a protein product. A functional assay may then test whether that protein or corrected cell behavior produces the expected biological result.
The point is not to add tests for the sake of volume. A defensible matrix maps each assay to a relevant part of the MOA. You choose methods that answer distinct questions: can the vector enter cells, can it express the intended product, does that product function, and does the method detect loss of activity when the product degrades? That last question matters because potency testing must also support stability decisions.
What Happens When A Gene Therapy Fails Potency Testing?
If a manufactured batch fails potency testing, it may not be releasable for clinical or commercial use. That can affect patient dosing schedules, clinical trial supply, manufacturing capacity, and regulatory confidence in the control strategy.
A failed result does not always mean the product itself is inactive. The assay may have excessive variability, weak controls, reagent drift, cell bank changes, operator sensitivity, or reference standard problems. That creates a hard operational problem: you need to determine whether the failure reflects the batch, the method, the materials, or the acceptance criterion.
This is why potency methods need meaningful controls and clear specifications. A product release specification should be scientifically justified, linked to biological activity, and capable of being applied lot after lot. If the assay cannot reliably distinguish acceptable product from degraded or weak product, the test may become a source of release uncertainty instead of a manufacturing control.
How To Design A Defensible Potency Assay Early—Before It Becomes A Crisis
You build a better gene therapy potency assay by starting with the MOA and working backward. Define the biological effect the therapy is meant to create, then choose assay readouts that measure the most relevant steps with enough precision for development, release, stability, and comparability use.
Early development methods do not need to look identical to final commercial methods, but they should point in the right direction. If your first assay only measures vector quantity, document why it is temporary and what functional readouts you plan to add. If your disease biology is complex, plan an assay matrix early rather than waiting until a late-stage regulatory review forces the issue.
You also need practical assay design criteria. The method should use controlled reagents, qualified cell banks when needed, defined controls, a reference standard strategy, and acceptance criteria that can mature as data accumulate. A useful potency assay is not just biologically elegant; it must survive routine manufacturing, analyst training, reagent changes, and repeated release decisions.
Validation, Stability, And Comparability: The Full CMC Picture
Potency assay validation shows that the method is suitable for its intended use. Depending on stage and purpose, you may need to demonstrate accuracy, precision, specificity, linearity or range, and the ability to detect meaningful changes in biological activity.
For stability, the assay must be stability-indicating. That means it should detect loss of activity during storage, handling, or product degradation. A method that remains unchanged when the product loses biological function does not give you a reliable way to set shelf life or evaluate storage conditions.
Comparability adds another test of assay quality. If you change manufacturing scale, process parameters, raw materials, formulation, site, or analytical methods, regulators expect evidence that pre-change and post-change product remain comparable. Potency data are often central to that argument because they connect process changes to biological performance.
Real-World Lessons And Future Directions For Gene Therapy Potency Testing
The first lesson is simple: potency cannot be bolted on at the end. If you wait until the Biologics License Application (BLA) stage to build a functional potency strategy, you leave too many variables unresolved at the exact moment regulators expect confidence.
The second lesson is that surrogate assays need a scientific bridge to function. Transduction, expression, or vector genome titer may support the potency argument, but they need justification that links them to the relevant biological activity. When the MOA includes several steps, a single surrogate can leave gaps that become hard to defend.
The third lesson is that good potency planning improves manufacturing decisions before approval. It helps you compare lots, assess process changes, evaluate stability, and investigate failures. A strong potency strategy gives you a clearer view of product quality, and it reduces the chance that an otherwise promising therapy gets slowed by an avoidable CMC problem.
What Test Can Make Or Break A Gene Therapy?
- A gene therapy potency assay measures specific biological activity.
- It supports lot release, stability, and comparability.
- Without a suitable test, approval can stall.
Build The Potency Strategy Before The Product Depends On It
A gene therapy potency assay is the test that connects manufacturing quality to biological function. It is different from identity, purity, and titer because it asks whether the product can do what it was designed to do. If your MOA is complex, you may need an assay matrix that measures several linked activities rather than one convenient surrogate. The safest path is to design, qualify, and refine potency testing early, then use it across release, stability, and comparability decisions. When you treat potency as a core CMC decision instead of a late analytical task, you give the therapy a better chance to move from manufacturing to patients without avoidable delays.
References
- eCFR — 21 CFR 600.3, Potency Definition
- FDA — Potency Tests For Cellular And Gene Therapy Products
- FDA — Chemistry, Manufacturing, And Control Information For Human Gene Therapy Investigational New Drug Applications
- FDA CBER — Cellular And Gene Therapy Products
- FDA — Approved Cellular And Gene Therapy Products
- European Medicines Agency — Guideline On Quality, Non-Clinical And Clinical Requirements For Investigational Advanced Therapy Medicinal Products.
Nirdosh Jagota is the Consultant & Managing Partner, GRQ Biotech Advisors. Nirdosh Jagota has over 30 years of experience in biotech and pharmaceutical industries, leading innovation in regulatory affairs and quality management.
Dr. Nirdosh Jagota has led global teams across US, Europe, Asia Pacific, Latin America, China, India, and Japan. His expertise has been instrumental in the successful submission, approval, and lifecycle management of biologics, small molecules, and vaccines.